fda glp-1 compounding enforcement october 2025 is short-sighted on GLP-1s New project announcement: HHS‑OIG is

This led to further research and the approval of some of these medications specifically for weight management in people without diabetes

Important Safety Reminders Medical Supervision Required: AOD-9604 should only be used under qualified medical supervision Baseline and monitoring laboratory testing is recommended Individual contraindications and health status must be evaluated AOD-9604 is not FDA-approved for any indication Contraindications and Precautions: Pregnancy and breastfeeding (no safety data available) Active malignancy (discuss with oncologist) Pediatric use (not studied in children) Significant organ dysfunction (limited safety data) Report Concerns: Any unexpected symptoms or adverse effects should be reported to your healthcare provider promptly

at Dock Street Theater, 135 Church St

For a full list of possible side effects, and other important safety information, please reference the Mayo Clinics list of Semaglutide side effects

doi: 10.1111/j.1600-0404.1999.tb07369.x 64

Some Cigna plans in Arizona may cover GLP-1 medications for weight loss when prescribed for a qualifying diagnosis and approved through prior authorization